Kura drug sends 35% of advanced leukemia cases into remission; Why Illumina CEO resigned

Grail's early-detection cancer blood tests made sense for Illumina on paper — but regulatory hurdles proved disastrous to the deal.

June 13, 2023 Check out STAT+

Sponsored By

CDC STAT+ | Kura Oncology highlights leukemia remission data as it enrolls larger trial Kura Oncology said Sunday its drug had sent 35% of cases of advanced leukemia into remission. By Andrew Joseph STAT+ | Francis deSouza's tenure at Illumina is a lesson in how not to handle CEO succession The roots of the resignation of CEO Francis deSouza lay in the original handoff from his predecessor, Jay Flatley. By Matthew Herper STAT+ | The inside story of how data integrity issues roiled a biotech seen as 'Moderna 2.0' At Laronde, a recent episode highlighted how easy it can be to get carried away with the promise of new therapies, despite signs of trouble. By Allison DeAngelis and Ryan Cross — The Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser